XML 63 R39.htm IDEA: XBRL DOCUMENT
v3.26.1

Commitments and Contingencies, Including License and Sponsored Research Agreements - Additional Information (Details) - USD ($) |  |  |  |  | 1 Months Ended | 12 Months Ended | 34 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Jan. 01, 2026 | Jan. 01, 2025 | Mar. 16, 2023 | Oct. 06, 2020 | Jun. 30, 2025 | Aug. 31, 2022 | Dec. 31, 2025 | Dec. 31, 2024 | Dec. 31, 2025 | May 04, 2023
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Accrued expenses |  |  |  |  |  |  | $ 3,612,913 | $ 1,388,060 | $ 3,612,913 |
Minimum |  |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Percentage of royalties owed on sublicense income |  |  |  |  |  | 10.00% |  |  |  |
Maximum |  |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Percentage of royalties owed on sublicense income |  |  |  |  |  | 20.00% |  |  |  |
DRL Agreement |  |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Pre-approval regulatory milestone payments |  |  | $ 2,900,000 |  |  |  |  |  |  |
Aggregate regulatory milestone payments |  |  |  |  |  |  | 1,200,000 |  | 1,000,000 |
Additional payments of other development and sales milestones |  |  | 20,000,000 |  |  |  |  |  |  |
Accrued expenses |  |  |  |  |  |  | 200,000 |  | 200,000 |
License agreement upfront fee |  |  | $ 400,000 |  |  |  |  |  |  |
ARScience License Agreement |  |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Aggregate regulatory milestone payments |  |  |  |  |  |  | 1,100,000 |  |  |
Accrued expenses |  |  |  |  |  |  | 700,000 |  | 700,000 |
Developmental milestones |  |  |  |  |  | $ 5,900,000 |  |  |  |
ARScience License Agreement | First Combination Product |  |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Developmental milestones |  |  |  |  |  | 13,300,000 |  |  |  |
ARScience License Agreement | Combination Product |  |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Developmental milestones |  |  |  |  |  | 11,600,000 |  |  |  |
ARScience License Agreement | First Mono Product |  |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Developmental milestones |  |  |  |  |  | 11,800,000 |  |  |  |
ARScience License Agreement | Mono Product |  |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Developmental milestones |  |  |  |  |  | $ 5,900,000 |  |  |  |
Methodist License |  |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Accrued expenses |  |  |  |  |  |  | $ 100,000 |  | $ 100,000 |
License termination condition description. |  |  |  |  |  |  | The Methodist License Agreement provides that in the event the Company sublicense products and services covered by the Methodist License Agreement, then royalties owed to Houston Methodist would be computed as a percentage of payments received by the Company from the sublicensee. In addition, the termination provisions provide that Houston Methodist may terminate the Methodist License Agreement, among other things, in the event that after five years the Company is not “Actively Attempting to Develop or Commercialize,” as such term is defined in the Methodist License Agreement. During the year ended December 31, 2025, the Company incurred $0.1 million in milestone payments to Methodist as in-process research and development expense, in connection with Company's FTD IND Milestone and Dosing Milestone. As of December 31, 2025, $0.1 million was included in accrued expenses in the accompanying balance sheets. |  |  |
Milestone payments |  |  |  |  |  |  | $ 100,000 |  |  |
Maximum aggregate amount payable upon milestone achievement of specific development and regulatory events. |  |  |  | $ 400,000 |  |  |  |  |  |
Minimum annual amount owned upon commercialization |  | $ 100,000 |  |  |  |  |  |  |  |
Methodist research fund |  |  |  |  |  |  |  |  |  | $ 500,000
Sponsored Research Agreement |  |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Minimum Total Funding |  |  |  |  | $ 1,200,000 |  |  |  |  |
Maximum Total Funding |  |  |  |  | $ 1,400,000 |  |  |  |  |
Research and development expenses |  |  |  |  |  |  | $ 1,000,000 | $ 500,000 |  |
Sponsored Research Agreement | Subsequent Event |  |  |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Maximum funding | $ 600,000 |  |  |  |  |  |  |  |  |

X
- Definition Achievement of developmental milestones + References No definition available. + Details
Name: | coya_AchievementOfDevelopmentalMilestones
Namespace Prefix: | coya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Additional payments of other development and sales milestones. + References No definition available. + Details
Name: | coya_AdditionalPaymentsOfOtherDevelopmentAndSalesMilestones
Namespace Prefix: | coya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate regulatory milestone payments. + References No definition available. + Details
Name: | coya_AggregateRegulatoryMilestonePayments
Namespace Prefix: | coya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Commitments and contingencies. + References No definition available. + Details
Name: | coya_CommitmentsAndContingenciesLineItems
Namespace Prefix: | coya_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreement upfront fee. + References No definition available. + Details
Name: | coya_LicenseAgreementUpfrontFee
Namespace Prefix: | coya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License termination condition description. + References No definition available. + Details
Name: | coya_LicenseTerminationConditionDescription
Namespace Prefix: | coya_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum aggregate amount payable upon milestone achievement of specific development and regulatory events. + References No definition available. + Details
Name: | coya_MaximumAggregateAmountPayableUponMilestoneAchievementOfSpecificDevelopmentAndRegulatoryEvents
Namespace Prefix: | coya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum funding. + References No definition available. + Details
Name: | coya_MaximumFunding
Namespace Prefix: | coya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum total funding. + References No definition available. + Details
Name: | coya_MaximumTotalFunding
Namespace Prefix: | coya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Methodist research fund. + References No definition available. + Details
Name: | coya_MethodistResearchFund
Namespace Prefix: | coya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestone payments. + References No definition available. + Details
Name: | coya_MilestonePayments
Namespace Prefix: | coya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Minimum annual amount owned upon commercialization. + References No definition available. + Details
Name: | coya_MinimumAnnualAmountOwnedUponCommercialization
Namespace Prefix: | coya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Minimum total funding. + References No definition available. + Details
Name: | coya_MinimumTotalFunding
Namespace Prefix: | coya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of royalties owed on sublicense income. + References No definition available. + Details
Name: | coya_PercentageOfRoyaltiesOwedOnSublicenseIncome
Namespace Prefix: | coya_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Pre-Approval Regulatory Milestone Payments + References No definition available. + Details
Name: | coya_PreApprovalRegulatoryMilestonePayments
Namespace Prefix: | coya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AccruedLiabilitiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=coya_LicenseAndSupplyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=coya_ArscienceBiotherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=coya_FirstCombinationProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=coya_CombinationProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=coya_FirstMonoProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=coya_MonoProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=coya_PatentKnowHowAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=coya_SponsoredResearchAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |